



ARCHIVIO ISTITUZIONALE DELLA RICERCA

Alma Mater Studiorum Università di Bologna Archivio istituzionale della ricerca

An international cohort study of autosomal dominant tubulointerstitial kidney disease due to REN mutations identifies distinct clinical subtypes

This is the final peer-reviewed author's accepted manuscript (postprint) of the following publication:

Published Version:

An international cohort study of autosomal dominant tubulointerstitial kidney disease due to REN mutations identifies distinct clinical subtypes / Zivna M.; Kidd K.; Zaidan M.; Vyletal P.; Baresova V.; Hodanova K.; Sovova J.; Hartmannova H.; Votruba M.; Treslova H.; Jedlickova I.; Sikora J.; Hulkova H.; Robins V.; Hnizda A.; Zivny J.; Papagregoriou G.; Mesnard L.; Beck B.B.; Wenzel A.; Tory K.; Haeffner K.; Wolf M.T.F.; Bleyer M.E.; Sayer J.A.; Ong A.C.M.; Balogh L.; Jakubowska A.; Laszkiewicz A.; Clissold R.; Shaw-Smith C.; Munshi R.; Haws R.M.; Izzi C.; Capelli I.; Santostefano M.; Graziano C.; Scolari F.; Sussman A.; Trachtman H.; Decramer S.; Matignon M.; Grimbert P.; Shoemaker L.R.; Stavrou C.; Abdelwahed M.; Belghith N.; Sinclair M.; Claes K.; Kopel T.; Moe S.; Deltas C.; Knebelmann B.; Rampoldi L.; Knoch S.; Bleyer A.J.. - In: KIDNEY INTERNATIONAL. - ISSN 0085-2538. - ELETTRONICO. - 98:6(2020), pp. 1589-1604. [10.1016/j.kint.2020.06.041]

This version is available at: <https://hdl.handle.net/11585/963228> since: 2024-02-28

Published:

DOI: <http://doi.org/10.1016/j.kint.2020.06.041>

Terms of use:

Some rights reserved. The terms and conditions for the reuse of this version of the manuscript are specified in the publishing policy. For all terms of use and more information see the publisher's website.

(Article begins on next page)

This item was downloaded from IRIS Università di Bologna (<https://cris.unibo.it/>).
When citing, please refer to the published version.

An International Cohort Study of Autosomal Dominant Kidney Disease due to *REN* Mutations
Identifies Distinct Subtypes

Martina Živná, PhD¹, Kendrah Kidd, MS^{1,2}, Mohamad Zaidan, MD, PhD³, Petr Vyleťal, PhD¹, Veronika Barešová, PhD¹, Kateřina Hodaňová, PhD¹, Jana Sovová¹, Hana Hartmannová, PhD¹, Miroslav Votruba¹, Helena Trešlová¹, Ivana Jedličková¹, Jakub Sikora¹, Helena Hůlková¹, Victoria Robins², Aleš Hnízda⁴, Jan Živný, PhD⁵, Gregory Papagregoriou, PhD⁶, Laurent Mesnard, MD⁷, Bodo B. Beck^{8,9}, Andrea Wenzel, PhD^{8,9}, Kálmán Tory, MD, PhD^{10,11}, Karsten Häeffner, MD¹², Matthias T.F. Wolf, MD¹³, Michael E. Bleyer, BS², John A. Sayer, MD PhD¹⁴⁻¹⁶, Albert C. M. Ong, DM¹⁷, Lídia Balogh, MD, PhD¹¹, Anna Jakubowska, MD¹⁸, Agnieszka Łaszkiwicz, PhD¹⁹, Rhian Clissold, MB ChB, MD²⁰, Charles Shaw-Smith, MD²⁰, Raj Munshi, MD^{21,22}, Robert M. Haws, MD²³, Claudia Izzi, MD²⁴, Irene Capelli, MD²⁵, Marisa Santostefano, MD²⁶, Claudio Graziano, MD²⁷, Francesco Scolari, MD, PhD²⁴, Amy Sussman, MD²⁸, Howard Trachtman, MD²⁹, Stephane Decramer, MD, PhD^{30,31}, Marie Matignon, MD^{32,33}, Philippe Grimbert, MD³²⁻³⁴, Lawrence R. Shoemaker, MD³⁵, , Christoforos Stavrou, MD³⁶, Mayssa Abdelwahed, PhD³⁷, Neila Belghith, MD^{37,38}, Matthew Sinclair, MD^{39,40}, Kathleen Claes, MD, PhD^{41,42}, Tal Kopel, MD⁴³, Sharon Moe, MD⁴⁴, Constantinos Deltas, PharmR, PhD⁶, Bertrand Knebelmann, MD, PhD⁴⁵⁻⁴⁷, Luca Rampoldi, PhD⁴⁸, Stanislav Kmoch, PhD^{1,2}, Anthony J. Bleyer, MD, MS^{1,2}

¹Research Unit of Rare Diseases, Department of Pediatric and Adolescent Medicine, First Faculty of Medicine, Charles University, Prague, Czech Republic; ²Section on Nephrology, Wake Forest School of Medicine, Winston-Salem, NC, USA; ³Service de Néphrologie-Transplantation, Hôpital de Bicêtre, Le Kremlin Bicêtre, France; ⁴ Department of Biochemistry, University of Cambridge, CB2 1TN Cambridge, UK; ⁵Institute of Pathophysiology, First Faculty of Medicine, Charles University, Prague, Czech Republic; ⁶Center of Excellence in Biobanking and Biomedical Research, Molecular Medicine Research Center, University of Cyprus, Nicosia, Cyprus; ⁷ Sorbonne Université, Urgences

Néphrologiques et Transplantation Rénale, Assistance Publique-Hôpitaux de Paris (APHP), Hôpital Tenon, Paris, France; ⁸University of Cologne, Faculty of Medicine and University Hospital Cologne, Institute of Human Genetics, Cologne, Germany; ⁹University of Cologne, Faculty of Medicine and University Hospital Cologne, Center for Molecular Medicine Cologne (CMMC) and Center for Rare Diseases Cologne (ZSEK), Cologne, Germany; ¹⁰MTA-SE Lendület Nephrogenetic Laboratory, Budapest, Hungary; ¹¹st Department of Pediatrics, Semmelweis University, Budapest, Hungary; ¹²Department of General Pediatrics, Adolescent Medicine and Neonatology, Medical Center, Faculty of Medicine, Universitätsklinikum Freiburg, Freiburg, Germany; ¹³Pediatric Nephrology, University of Texas Southwestern Medical Center, Dallas, TX, USA; ¹⁴Renal Services, The Newcastle Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom; ¹⁵Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Central Parkway, Newcastle upon Tyne, United Kingdom; ¹⁶NIHR Newcastle Biomedical Research Centre, Newcastle University, NE4 5PL, United Kingdom; ¹⁷Kidney Genetics Group, Academic Nephrology Unit, Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield Medical School, Sheffield, United Kingdom; ¹⁸Department of Pediatric Nephrology Medical University Wroclaw, Poland; ¹⁹Laboratory of Molecular and Cellular Immunology, Hirsfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroclaw, Poland; ²⁰Exeter Kidney Unit, Royal Devon and Exeter NHS Foundation Trust, Barrack Road, Exeter, Devon, United Kingdom; ²¹Division of Nephrology, Department of Pediatrics, Seattle Children's Hospital, Seattle, WA, USA; ²²University of Washington, Seattle, WA, USA; ²³Pediatrics – Nephrology, Marshfield Medical Center, Marshfield, WI; ²⁴Division of Nephrology and Dialysis, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia and Montichiari Hospital, Brescia, Italy; ²⁵Department of Experimental Diagnostic and Specialty Medicine (DIMES), Nephrology, Dialysis and Renal Transplant Unit, S. Orsola Hospital, University of Bologna, Bologna, Italy;

²⁶Division of Nephrology, Ospedale Sant'Orsola-Malpighi, Bologna, Italy; ²⁷Medical Genetics Unit, Policlinico S. Orsola-Malpighi, Bologna Italy; ²⁸Department of Medicine, Division of Nephrology, University of Arizona Health Sciences Center, Tucson, AZ, USA; ²⁹Division of Nephrology, Department of Pediatrics, NYU School of Medicine, New York, NY, USA; ³⁰Pediatric Nephrology, CHU Purpan, Toulouse, France; ³¹France Rare Renal Disease Reference Centre (SORARE), Toulouse, France;

³²AP-HP (Assistance Publique-Hôpitaux de Paris), Nephrology and Renal Transplantation Department, Institut Francilien de Recherche en Néphrologie et Transplantation (IFRNT), Groupe Hospitalier Henri-Mondor/Albert-Chenevier, Créteil, France; ³³Université Paris-Est-Créteil, (UPEC), DHU (Département Hospitalo-Universitaire) VIC (Virus-Immunité-Cancer), IMRB (Institut Mondor de Recherche Biomédicale), Equipe 21, INSERM U 955, Créteil, France; ³⁴AP-HP (Assistance Publique-Hôpitaux de Paris), CIC-BT 504, Créteil, France; ³⁵Division of Nephrology, Department of Pediatrics, University of Florida, Gainesville, FL, USA; ³⁶Evangelismos Private Hospital, Pafos, Cyprus;

³⁷Laboratory of Human Molecular Genetics, Faculty of Medicine, University of Sfax, Tunisia;

³⁸Medical Genetics Department of Hedi Chaker Hospital, Sfax, Tunisia; ³⁹Division of Nephrology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA; ⁴⁰Duke Clinical Research Institute, Durham, NC, USA; ⁴¹Department of Nephrology and Renal Transplantation, University Hospitals Leuven, Belgium; ⁴²Laboratory of Nephrology, Department of Microbiology and Immunology, Katholieke Universiteit (KU) Leuven, Leuven, Belgium; ⁴³Nephrology Division, University of Montreal Hospital Centre, Hopital Saint-Luc, Montreal, Quebec, Canada; ⁴⁴Division of Nephrology, Indiana University School of Medicine, Indianapolis, IN, USA; ⁴⁵Department of Nephrology-Transplantation, Necker Hospital, APHP, Paris, France; ⁴⁶Paris Descartes University, Sorbonne Paris Cité, Paris, France; ⁴⁷Département Biologie cellulaire, INSERM U1151, Institut Necker Enfants Malades, Paris, France; ⁴⁸Molecular Genetics of Renal Disorders, Division of Genetics and Cell Biology, IRCCS San Raffaele Scientific Institute, Milan, Italy

Corresponding Author

Anthony J. Bleyer, MD, MS

Wake Forest School of Medicine

Section on Nephrology

Winston-Salem, NC, USA 27157

Fax: 336-716-4318

Phone: 336-716-4650

e-mail: ableyer@wakehealth.edu

RUNNING HEAD

Distinct subtypes of ADTKD-*REN* in an international cohort study

WORD COUNT: 4000

1 **ABSTRACT**

2 There have been few clinical or scientific reports of autosomal dominant tubulo-interstitial kidney
3 disease due to *REN* mutations (ADTKD-*REN*), limiting characterization. We formed an international
4 cohort that characterized 111 individuals from 30 families both clinically and in the laboratory. Sixty-
5 nine (62%) individuals had a *REN* mutation in the signal peptide region (signal group), 27 (24%) in the
6 prosegment (prosegment group), and 15 (14%) in the mature renin peptide (mature group). Signal
7 group patients were most severely affected, presenting at a mean age of 19.7 ± 15.7 years, with the
8 prosegment group presenting at 22.4 ± 20.2 years, and the mature group at 37 ± 12.4 years. Anemia was
9 present in childhood in 91% in the signal group, 69% prosegment, and 0 of the mature group. *REN* signal
10 peptide mutations reduced the signal peptide's hydrophobicity, which is necessary for recognition and
11 translocation across the endoplasmic reticulum (ER) membrane, leading to aberrant delivery of
12 preprorenin into the cytoplasm. *REN* mutations in the prorenin segment led to deposition of prorenin
13 and renin in the endoplasmic reticulum Golgi intermediate compartment (ERGIC) and decreased
14 prorenin secretion. Mutations in mature renin led to deposition of the mutant prorenin in the
15 endoplasmic reticulum, similar to patients with ADTKD-*UMOD*, with a rate of progression to ESKD
16 (63.6 ± 7.6 y) that was significantly slower vs. the signal (50.8 ± 17.6 y) and prosegment groups (53.1 ± 10.6
17 years) (hazard ratio 0.367, $p=0.023$). Clinical and laboratory studies revealed subtypes of ADTKD-*REN*
18 that are pathophysiologically, diagnostically, and clinically distinct.

19

20 **KEY WORDS**

21 Autosomal dominant tubulo-interstitial kidney disease, renin, mutation, characterization, signal peptide,
22 prosegment,

23

24 INTRODUCTION

25 Autosomal dominant tubulo-interstitial kidney disease (ADTKD) is characterized by autosomal dominant
26 inheritance, bland urinary sediment, and slowly progressive chronic kidney disease (CKD) leading to end-
27 stage kidney disease (ESKD) between 30 and 80 years (1). While ADTKD was described in fewer than 10
28 families prior to 1990, genetic testing has led to increased detection, with over 300 families reported (2-
29 5). ADTKD due to mutations in the *REN* gene encoding renin (ADTKD-*REN*) is one of the least common
30 forms of ADTKD (5), with only 8 families and 28 individuals reported before 2020 (5-11).

31 Renin is a hormone primarily produced in the kidney that is requisite for tubulogenesis (12) and
32 embryonic kidney formation (13). The renin angiotensin system (RAS) is a key modulator of blood
33 pressure (14) and CKD progression (15). Renin biosynthesis constitutes the first enzymatic steps in the
34 RAS. The human renin precursor is synthesized in the juxtaglomerular cells of the macula densa as a 406
35 amino acid preprorenin, composed of a 23 amino acid N-terminal signal peptide, a 43 amino acid
36 prosegment, and a 340 amino acid mature renin peptide (16). During biosynthesis, the signal peptide
37 mediates insertion of the nascent preprorenin into the translocation channel in the endoplasmic
38 reticulum (ER) and initiates cotranslational translocation of preprorenin into the ER lumen, where
39 glycosylation and proteolytic processing of the nascent preprorenin occur, conditioning further transit of
40 prorenin and renin through the constitutive and regulated secretory pathways (17).

41 In ADTKD-*REN*, heterozygous *REN* mutations lead to decreased synthesis of prorenin and renin,
42 resulting in mild hyperkalemia, anemia, hyperuricemia, and a predisposition to the development of
43 acute kidney injury (5). *REN* mutations have been reported in the segment of the *REN* gene encoding
44 the signal peptide (5-8) and the mature renin protein (9, 10). Mutations in the prosegment – a segment
45 of the gene after the signal peptide that assists in protein folding – have not been reported. The small

46 number of case reports of ADTKD-*REN* has prevented clinical correlation with mutation type and
47 identification of risk factors for progression to ESKD.

48 We performed an international retrospective cohort study and collected clinical and genetic
49 data on 111 individuals from 30 families with heterozygous *REN* mutations in order to better
50 characterize this condition. We performed laboratory investigations on ten representative mutations
51 (five in the signal peptide, three in the prosegment, and two in mature renin) and characterized two
52 missense *REN* variants of unknown significance found in African-Americans, p.P8A and p.R33W.

53 **RESULTS**

54 Of 111 individuals from 30 families (see Table 1 and Supplementary Figures S1, S2), sixty-nine (62%)
55 individuals had a mutation in the signal peptide, 27 (24%) in the prosegment, and 15 (14%) in the
56 mature renin peptide. A mutation in p.S45N was identified in one individual with ADTKD of unknown
57 cause. This mutation did not segregate with disease and was determined to be nonpathogenic; it was
58 included as a control for laboratory investigations. While searching variant databases, we noticed two
59 additional rare missense variants (AA-*REN* variants) found specifically in African-Americans, a group
60 with an increased prevalence of low-renin hypertension and CKD (18). These variants encode p.P8A in
61 the signal peptide and p.R33W in the prosegment of preprorenin. Their allelic frequencies in African-
62 Americans are 0.007 and 0.001 respectively.

63 **Effect of Mutation Class on Clinical Characteristics**

64 **Presentation**

65 After excluding patients with missing data (n=14) and those identified by genetic screening (n=16), there
66 were 81 patients for analysis (see Table 2). Patients in the signal group were the most severely affected
67 and presented at the youngest age. The mean age of clinical presentation was 19.7±15.7 years for the
68 signal group, 22.4±20.2 years for the prosegment group, and 37.0±12.4 years for the mature group

69 ($p < 0.001$ for comparison of the mature group vs. signal and prosegment group). Only patients in the
70 signal group presented with acute kidney injury (10%) or acidosis, anemia, and kidney failure (13%).
71 Thirty-one percent of patients in the signal group and 50% of patients in the prosegment group
72 presented with anemia. Patients in the mature group presented only with gout (75%) or CKD (25%).
73 The mean age of presentation was similar for men and women (19.3 ± 13.7 years vs. 19.9 ± 19.4 years,
74 $p = 0.6$).

75 **Kidney function**

76 Kidney function was less severely affected in the mature group vs. the signal and prosegment groups.
77 Figure 1A displays all estimated glomerular filtration (eGFR) values obtained for the entire cohort of
78 patients. An eGFR of $10 \text{ mL/min/1.73m}^2$ was assigned at the age of ESKD. Patients in the signal and
79 prosegment group presented much earlier in life. At earliest clinical presentation, the majority of eGFR
80 readings in these groups were below $60 \text{ mL/min/1.73 m}^2$, suggesting that decreased kidney function is
81 present at birth in most patients. Despite early decreased function, eGFR values tended to remain
82 relatively stable during childhood and through adolescence. Figure 1B shows data on 13 children in the
83 signal group with multiple eGFR measurements. In almost all cases, eGFR remained steady with minimal
84 decline, including one patient whose eGFR remained stable at approximately $30 \text{ mL/min/1.73m}^2$ from
85 age 2 through age 16 (Figure 1B: p.C20R with red markers). Another patient (p.M39K) presented during
86 infancy with an eGFR of $19 \text{ mL/min/1.73 m}^2$ and had a relatively stable eGFR through childhood before
87 proceeding to renal replacement therapy at 15 years, being the only individual reaching ESKD prior to
88 age 30 years. After adolescence, there was in general a slow decline in eGFR in the signal and
89 prosegment groups (see Figure 1A). The median age of ESKD was 57 years in the signal group, 62 years
90 in the prosegment group, and 68 years in the mature group (Figure 2). Patients in the mature group had
91 no laboratory values until age 20 years, due to milder manifestations (see Figure 1A). Patients in the
92 mature group presenting at this age appeared to have normal kidney function.

93 To evaluate risk factors for ESKD progression, univariate Cox proportional hazards models were
94 created, with the event being age of ESKD. Patients in the mature group had a significantly decreased
95 risk of developing ESKD over time vs the signal and prosegment groups combined, with a hazard ratio of
96 0.37 (p=0.023) (See Table 3 and Figure 2). In other univariate models, anemia in childhood (hazard ratio
97 2.82, p=0.03) (See Table 3 and Figure 3) was significantly associated with an earlier age of ESKD, while
98 gender was not associated with progression to ESKD. The best-fit Cox proportional hazards model
99 included only anemia in childhood (See Table 3 and Figure 3).

100 **Anemia**

101 Figure 4A shows hemoglobin levels in patients not on erythropoietin. The lowest hemoglobin values
102 were 7.5 g/dL. The mean hemoglobin level was 9.6 ± 1.04 g/dL for age <10 years, 10.1 ± 1.1 g/dL for 10 to
103 <15 years, and 10.5 ± 1.2 g/dL for ages 15 to < 20y. Females were more likely to have anemia as a child
104 (97% vs. 46%, p=0.005) and have lower hemoglobin levels (see Table 4 and Figure 4A). Hemoglobin
105 levels in women tended to remain low over time, while in men, hemoglobin levels appeared to rise after
106 age 20 years. For 14 children who never received erythropoietin, the mean hemoglobin level was
107 9.8 ± 1.2 g/dL (range 7.4-13.8 g/dL). For children who received erythropoietin, while not receiving
108 erythropoietin the mean hemoglobin level was 10.1 ± 1.3 g/dL (range 7.6-12.6 g/dL).

109 **Hyperkalemia and acidemia**

110 Hyperkalemia was present but rarely reach life-threatening levels. Figure 4 shows serum potassium
111 according to age (4B) and eGFR (4C). Serum bicarbonate levels vs. age are depicted in Figure 4D. Serum
112 bicarbonate values were frequently below 24 mEq/L.

113 **Gout**

114 In individuals not taking allopurinol or febuxostat, males had a higher serum urate level than women
115 (9.4 ± 2.7 mg/dl vs. 7.7 ± 1.6 mg/dl, p=0.02) and were more likely to have gout (49.3% vs. 39.5%, p<0.01).

116 **Renin levels**

117 Plasma renin levels were low, with the mean random plasma renin activity (normal range 2.9 to 24
118 ng/mL/h) in the signal group 0.5 ± 0.8 ng/ml/h (n=18), in the prosegment group 0.5 ± 0.6 ng/ml/h (n=4),
119 and in the mature group 0.8 ± 0.7 ng/ml/h (n=5).

120 **Fludrocortisone**

121 Fludrocortisone was administered to two patients consistently and in seven patients for a short period
122 of time. There were no adverse effects from fludrocortisone. In one patient, it was taken consistently
123 from age 11 onwards, and in another patient from age 13 (Figure 5). The serum potassium values were
124 lower in nine individuals while taking vs. not taking fludrocortisone (4.37 ± 0.54 mEq/L vs 4.77 ± 0.55
125 mEq/L, $p < 0.01$). The serum bicarbonate values were also higher (25.9 ± 2.3 mEq/L vs. 23.7 ± 3.5 mEq/L,
126 $p=0.003$).

127 **In silico analysis**

128 **Figure 6A** displays the *REN* mutations identified in ADTKD families. Except for the p.T26I and the non-
129 pathogenic p.S45N, all amino acid residues at mutation sites are absolutely conserved across species
130 (**Figure 6B**). SignalP 4.1 prediction software (19) indicates that all signal peptide mutations except
131 p.C20R decrease the cleavage site prediction scores (C-score) (**Figure 6C**), suggesting a decrease in the
132 efficacy of the signal peptidase mediated release of the signal peptide from prorenin. Scores for the
133 AA_*REN* p.P8A variant are similar to wild type (**Figure 6C**). The mutations in the prosegment, including
134 the AA_*REN* variant p.R33W, are classified by the M-CAP pathogenicity classifier (20) as either likely
135 benign (p.T26I, p.M39K and p.S45N (non-pathogenic)) or possibly pathogenic (p.R33W). Mutations in
136 mature renin (p.C325R, p.I366N) are classified as possibly pathogenic (**Figure 6D**).

137 All mutations have significant effects on prorenin structure (**Figure 7**) and may modulate renin activity
138 by affecting the folding, constitutive secretion and proteolytic processing of prorenin (21-23).

139 **Functional studies of identified *REN* variants**

140 Wild type and mutant proteins were transiently expressed in HEK293 cells (**Figure 8**). Western blot and
141 immuno-detection of corresponding proteins showed that the wild type protein was present in the cell
142 lysate in three major forms (Figure 8A) corresponding to preprorenin (45 kDa), prorenin (47 kDa) and
143 renin (43 kDa), with the preprorenin being less abundant. In the culture media (Figure 8B), only prorenin
144 was detected. Proteins with mutations in the signal peptide were present in cell lysates mostly in the
145 form of preprorenin, with no prorenin or renin detected in culture media. Proteins with mutations
146 p.T26I and p.M39K in the prosegment were present in cell lysates in all three forms similar to the wild
147 type protein, whereas the nonpathogenic p.S45N was present mostly in the form of prorenin.
148 Prosegment mutations affected secretion of p.M39K prorenin into culture media; however, secretion of
149 p.T26I and p.S45N was unaffected. Proteins with mutations in the mature renin were present in cell
150 lysate predominantly as prorenin and were not secreted into culture media. Proteins with AA_*REN*
151 variants in the signal peptide (p.P8A) or prosegment (p.R33W), showed similar profiles to wild type
152 protein in cell lysates. The mutation p.R33W affected secretion of prorenin into culture media (**Figure**
153 **8A,B**). Quantitative immunoradiometric assay (**Figure 8E,F**) showed that mutations in the signal peptide
154 either significantly reduced (p.L16del) or entirely prevented renin and prorenin synthesis in cells and
155 their secretion into culture media. Mutations in the prosegment had either no effect or a marginal effect
156 (p.M39K) on renin and prorenin synthesis, but affected secretion of p.T26I and p.M39K into culture
157 media. Secretion of nonpathogenic p.S45N was unaffected. Mutations in the mature renin led to the
158 synthesis of prorenin and renin that were either inactive or undetectable by the antibody used in the
159 assay. The AA_*REN* variant p.P8A had no effect on renin and prorenin synthesis in cells and secretion of
160 prorenin and renin into the culture media. For the AA_*REN* variant p.R33W, there was reduced secretion
161 of prorenin into the culture media (**Figure 8C, D**). Proteolytic activity assay showed that mutations in the
162 signal peptide either reduced (p.L16del) or entirely abolished renin activity in culture media. Mutations

163 in the prosegment led either to a production of proteolytically “hyperactive” prorenin (p.M39K) or
164 reduced the activity of renin in the culture media (p.T26I, p.S45N). Mutations in the mature renin
165 abolished production of active renin. The AA_*REN* variant p.P8A had no effect on the proteolytic activity
166 of secreted renin and prorenin. The AA_*REN* variant p.R33W reduced renin activity via low prorenin
167 secretion (**Figure 8E, F**). Mutated proteins had altered intracellular localization (**Figure 9A**). Wild type
168 protein was present in coarsely granular structures that were localized in the cytoplasm and in the
169 LAMP2 positive lysosomal-like structures. Proteins with signal peptide mutations demonstrated mostly
170 diffuse cytoplasmic staining. Proteins with prosegment mutations were localized mainly to endoplasmic
171 reticulum intermediate compartment (ERGIC). Proteins with mutations in the mature renin formed
172 intracellular clumps localized in the ER (**Figures 9A,B, Supplementary Figure S3**). There was little renin
173 staining in the Golgi apparatus for wild-type and *REN* mutations (**Supplementary Figure S4**). Wild type
174 protein and proteins with prosegment mutations were localized in lysosomes whereas proteins with
175 signal peptide mutations (except of p.L16del) and proteins with mutations in the mature renin were not
176 (**Supplementary Figure S5**). All functional data are summarized in **Table 5**.

177 DISCUSSION

178 In this work we describe distinct clinical and pathophysiologic differences (**Figure 10**) in signal,
179 prosegment, and mature peptide mutations of the *REN* gene in a cohort of 111 patients from 30 families
180 with ADTKD-*REN*.

181 Patients with mutations in the signal peptide region were the most severely affected. One-third
182 presented before age 10, with 10% having acute kidney injury and 13% presenting with anemia, acidosis,
183 and kidney failure. The mean age of presentation was lower than in the other two groups (19.7±15.7
184 years vs. 22.4±20.2 years and 37.0±12.4 years). We demonstrated that transiently expressed proteins
185 with mutations in the signal peptide lead to proteosynthesis of preprorenin that, according to

186 immunofluorescence studies, is probably located in the cytoplasm or faces the cytoplasmic side of the
187 ER or ERGIC membranes. This phenomena has previously been described in a case of signal peptide
188 mutations of preproinsulin leading to β cell failure and autosomal dominant diabetes (24, 25) and in a
189 mutation in the preproparathyroid hormone (*PTH*) gene resulting in familial isolated
190 hypoparathyroidism (26). The effects of aberrant renin production not only resulted in manifestations of
191 clinical renin deficiency but likely also affected normal renal embryogenesis, resulting in decreased
192 kidney function at birth. The presence of significantly decreased renin activity in the setting of a
193 heterozygous mutation is likely due to the mutated protein blocking the translocon and affecting
194 synthesis of functional renin from the wild-type allele, a phenomenon that has been observed in ADTKD
195 caused by mutations of Translocon Subunit Alpha 1 (SEC61A1) (4) or in preproinsulin signal peptide
196 mutations, resulting in permanent neonatal diabetes, despite the presence of a wild-type insulin allele
197 (27).

198 61% of individuals in the prosegment group presented at less than 10 years (61%), often
199 presenting with gout (36%) and anemia (50%). The prosegment (propeptide) is a structural element that
200 determines the biosynthesis, cellular trafficking and function of most proteases (28), including prorenin
201 (21-23). Mutations in the prosegment leading to dominant phenotypes have been reported in several
202 other preproteins, including proinsulin (leading to diabetes) (29) and factor IX deficiency (haemophilia)
203 (30). The prosegment mutations in prorenin described here are classified as likely benign by various
204 pathogenicity prediction programmes. However, based on structural studies, they are predicted to
205 change interactions of the prosegment region with renin that are critical for the maintenance of the
206 protease in its inactive state [24]. Accordingly, we demonstrated that mutations in the prosegment do
207 not significantly affect the amounts of synthesized prorenin and renin, but rather they alter secretion
208 and enzyme activity regulating properties of the prosegment as demonstrated by altered proportions of
209 synthesized, enzymatically active renin and prorenin (**Table 5**). This altered proportion may also reflect

210 the effect of prosegment mutations on trafficking through the intracellular vesicular network, within
211 which processing of prorenin to renin occurs. Such an effect is suggested by specific accumulation of
212 proteins with prosegment mutations (compared to other *REN* mutations) in the ER-Golgi intermediate
213 compartment (ERGIC), where the quality control system of the early secretory pathway and the
214 concentration process of nascent secretory proteins into secretory granules take place (31). The age of
215 presentation and severity of prosegment mutations may vary significantly due to the type of mutation
216 and its specific effects on biosynthesis, cellular trafficking and proteolytic processing of prorenin and
217 renin activity regulation. In addition to causing cellular toxicity, these dominant negative effects may be
218 due to abnormal interactions between the mutant and wild-type proteins that are being processed in
219 parallel, as seen in early onset insulin-deficient diabetes (32). The non-pathogenic p.S45N variant
220 showed normal *in vitro* scores and normal (actually increased) enzyme activity. Accumulation in the
221 ERGIC however suggests that the p.S45N mutation affects protein trafficking and could potentially lead
222 to late-onset CKD.

223 Mutations in the genetic region encoding the mature renin peptide had a much milder course
224 compared to patients with mutations in the region encoding the signal peptide or preprorenin, as first
225 noted by Schaeffer in a case report of a family with the p.L381P *REN* mutation (11). In contrast to
226 patients in the signal and prosegment group who often present in childhood, patients in the mature
227 group first present in their twenties with gout or present later in life with unexplained CKD. These
228 patients appear to have normal kidney function early in life. Whether individuals in the mature group
229 had anemia in childhood is unclear, but if present it was asymptomatic in the patients in our cohort.
230 Two mutations in mature renin were studied *in vitro*. These mutations destabilize renin structure and
231 produce an enzymatically inactive prorenin that is trapped within the ER, similar to the mature *REN*
232 mutation p.L381P (11). The localization of the mutated mature renin protein and pathophysiologic
233 changes are very similar to changes found in ADTKD due to *UMOD* mutations, and the two conditions

234 are quite similar clinically. Better clinical outcomes in the mature group may be due to decreased
235 cellular toxicity of the mature renin mutations and decreased effects on cellular processing of the wild-
236 type renin produced by the normal allele, similar to mutations in the mature insulin peptide found in
237 diabetes mellitus, with onset of symptoms in adulthood (33-35).

238 *REN mutations identified in African-Americans*

239 We also evaluated two missense *REN* variants of unknown significance, p.P8A and p.R33W, which are
240 located in the signal peptide and prosegment of preprorenin and are present in relatively high
241 frequencies in African-Americans. Individuals of African descent show a higher prevalence of low renin
242 hypertension and ESKD (18), and we were interested to evaluate their functional impact. Our analyses
243 demonstrated that whereas the p.P8A variant has no effect, the p.R33W variant has altered properties
244 that are very similar to other ADTKD-*REN* prosegment mutations. With population frequencies of 0.001
245 the p.R33W may thus represent a genetic factor contributing to heritability of low circulating plasma
246 renin and CKD in a small group of African-Americans. We were unable to recruit and study any
247 individuals with the p.R33W mutation, who could have mild hyperkalemia, gout, and CKD with aging.

248 While this is the largest study of patients with ADTKD-*REN*, the small number of participants still
249 limited our ability to assess the effects of fludrocortisone. Moreover, data was limited in teenage males
250 and patients in the mature group. As the study was retrospective and these individuals were
251 asymptomatic, there was no need for clinicians to perform laboratory studies earlier in life. We are
252 interested in adding further families to our registry in order to improve clinical characterization, and we
253 would appreciate information on other families with this disorder (please contact
254 ableyer@wakehealth.edu).

255 In summary, families with ADTKD-*REN* can be divided into three groups. Patients with
256 mutations in the region encoding the mature peptide present with gout in early adulthood or CKD later

257 in life. Their course is milder than in patients with mutations in the regions encoding the signal peptide
258 and prosegment. In these latter two groups, kidney function appears to be decreased starting from birth
259 in many patients but remains stable through early adulthood. Anemia, hyperkalemia, and acidosis are
260 frequently present, with acidosis being inadequately treated in a number of patients. Fludrocortisone
261 raises eGFR, lowers serum potassium, and improves serum bicarbonate, but only a few patients received
262 treatment with this medication, limiting our abilities to understand advantages and disadvantages of
263 treatment.

264 **METHODS**

265 This investigation was approved by the institutional review boards of the participating centers and was
266 carried out in accordance with the Declaration of Helsinki.

267 **Identification of cases**

268 Between January 1, 2019 and February 29, 2020, the literature was reviewed for families reported with
269 heterozygous *REN* mutations, and the authors were contacted for additional information regarding
270 affected patients. Academic centers with an interest in ADTKD were contacted and asked to provide
271 clinical and genetic data from families with ADTKD-*REN* that had not been reported (**Supplementary**
272 **Figure S1**). Investigators were asked to provide the following information for each individual from birth
273 through February 29, 2020: mutation, age and reason for presentation, all hemoglobin values and use of
274 erythropoietin, all serum electrolyte, uric acid, blood urea nitrogen and creatinine values, the age of
275 onset of ESKD, and the use of fludrocortisone, allopurinol, or alkali supplementation. These mutations
276 were not present in the Genome Aggregation Database (36) and segregated with disease in affected
277 families, with the exception of p.S45N, which was found not to segregate with disease in the one family
278 found to have this mutation.

279 **Genetic evaluation**

280 *REN* mutations were identified using either Sanger sequencing of individual *REN* exons, panel
281 sequencing or whole exome sequencing essentially as described (4, 5).

282 **Calculation of estimated glomerular filtration rate**

283 The estimated glomerular filtration rate (eGFR) was determined using the Pottel equation (37). This
284 equation takes into account age, gender, and serum creatinine values. It was specifically chosen
285 because it has been shown to be accurate in all age groups and allows for a continued comparison of
286 data from childhood into adulthood (37), a critical period of analysis in this cohort.

287 **Statistical analysis**

288 Statistical analysis was carried out using SAS statistical software (Cary, NC), using standard analytical
289 tests such as the T-test, Chi-squared test, multivariate regression, and Cox proportional hazards
290 regression. For comparison of laboratory values (including serum potassium, uric acid, hemoglobin, and
291 bicarbonate), the mean values for each patient were determined and compared with the mean values of
292 other patients. This analysis was chosen to maximize the use of data while also controlling for an
293 increased number of measurements for some individuals.

294 **In *silico* analysis**

295 Properties of the signal sequences were assessed as described (5, 6). Mutations were mapped into the
296 prorenin structure (PDB ID 3VCM). Structural models were visualized using Pymol Viewer (DeLano
297 Scientific Palo Alto, CA, USA).

298 **Transient expression of preprorenin in HEK293 cells**

299 Wild type *REN* cloned into pCR3.1 a eukaryotic expression vector was used and corresponding mutated
300 constructs were prepared by site-directed mutagenesis as in our previous study (5, 6). Transfection,

301 qualitative and quantitative assays and immunofluorescence analysis of renin were performed as
302 described in (5, 6) and in **Supplementary methods**.

303

304 **DISCLOSURE STATEMENT**

305 Authors have nothing to disclose.

306

307 **ACKNOWLEDGEMENTS**

308 We thank all participating patients and families, and the referring physicians. We thank Dr. Heike Göbel
309 (Institute of Pathology, University Hospital of Cologne, Cologne, Germany) and Dr. Helmut Hopfer
310 (Institute of Pathology, University Hospital Basel, Basel, Switzerland) for providing renal sections. This
311 study was supported by grant NV17-29786A from the Ministry of Health of the Czech Republic and by
312 institutional programs of Charles University in Prague (UNCE/MED/007 and PROGRES-Q26/LF1). The
313 National Center for Medical Genomics (LM2018132) kindly provided sequencing and genotyping. AJB
314 was funded by the Slim Health Foundation, the Black-Brogan Foundation, and NIH-NIDDK R21
315 DK106584. KT was supported by MTA-SE Lendulet Research Grant (LP2015-11/2015). JAS is supported
316 by Kidney Research UK and the Northern Counties Kidney Research Fund. BBB and AW were supported
317 by intramural grants from the Koeln Fortune Program/Faculty of Medicine (grant KF Nr 245/2011, grant
318 KF Nr 172/2013, and grant KF 472/18), University of Cologne, Germany. LR was supported by the Italian
319 Society of Nephrology (SIN) under the “Adotta un progetto di ricerca” program, Telethon-Italy
320 (GGP14263); the Italian Ministry of Health (grant RF-2010-2319394), Soli Deo Gloria.

REFERENCES

1. Devuyst O, Olinger E, Weber S, et al. Autosomal dominant tubulointerstitial kidney disease. *Nat Rev Dis Primers*. 2019;5:60.
2. Hart TC, Gorry MC, Hart PS, et al. Mutations of the UMOD gene are responsible for medullary cystic kidney disease 2 and familial juvenile hyperuricaemic nephropathy. *J Med Genet*. 2002;39:882-892.
3. Kirby A, Gnirke A, Jaffe DB, et al. Mutations causing medullary cystic kidney disease type 1 lie in a large VNTR in MUC1 missed by massively parallel sequencing. *Nat Genet*. 2013;45:288-393.
4. Bolar NA, Golzio C, Zivna M, et al. Heterozygous Loss-of-Function SEC61A1 Mutations Cause Autosomal-Dominant Tubulo-Interstitial and Glomerulocystic Kidney Disease with Anemia. *Am J Hum Genet*. 2016;99:174-187.
5. Zivna M, Hulkova H, Marignon M, et al. Dominant renin gene mutations associated with early-onset hyperuricemia, anemia, and CKD. *Am J Human Genet*. 2009;85:204-213.
6. Bleyer AJ, Zivna M, Hulkova H, et al. Clinical and molecular characterization of a family with a dominant renin gene mutation and response to treatment with fludrocortisone. *Clin Nephrol*. 2010;74:411-422.
7. Beck BB, Trachtman H, Gitman M, et al. Autosomal dominant mutation in the signal peptide of renin in a kindred with anemia, hyperuricemia, and CKD. *Am J Kidney Dis*. 2011;58:821-825.
8. Clissold RL, Clarke HC, Spasic-Boskovic O, et al. Discovery of a novel dominant mutation in the REN gene after forty years of renal disease: a case report. *BMC Nephrol*. 2017;18:234.
9. Petrijan T, Menih M. Discovery of a Novel Mutation in the REN Gene in Patient With Chronic Progressive Kidney Disease of Unknown Etiology Presenting With Acute Spontaneous Carotid Artery Dissection. *J Stroke Cerebrovasc Dis*. 2019;28:104302.

10. Abdelwahed M, Chaabouni Y, Michel-Calemard L, et al. A novel disease-causing mutation in the Renin gene in a Tunisian family with autosomal dominant tubulointerstitial kidney disease. *Int J Biochem Cell Biol.* 2019;117:105625.
11. Schaeffer C, Izzi C, Vettori A, et al. Autosomal Dominant Tubulointerstitial Kidney Disease with Adult Onset due to a Novel Renin Mutation Mapping in the Mature Protein. *Sci Rep.* 2019;9:11601.
12. Gribouval O, Gonzales M, Neuhaus T, et al. Mutations in genes in the renin-angiotensin system are associated with autosomal recessive renal tubular dysgenesis. *Nat Genet.* 2005;37:964-968.
13. Gomez RA, Sequiera-Lopez MLS. Renin cells in homeostasis, regeneration and immune defence mechanisms. *Nat Rev Nephrol.* 2018;14:231-245.
14. Pugliese NR, Masi S, Taddei S. The renin-angiotensin-aldosterone system: a crossroad from arterial hypertension to heart failure. *Heart Fail Rev.* 2020;25:31-42.
15. Sparks MA, Crowley SD, Gurley SB, Mirotso M, Coffman TM. Classical Renin-Angiotensin system in kidney physiology. *Compr Physiol.* 2014;4:1201-1228.
16. Imai T, Miyazaki H, Hirose S, et al. Cloning and sequence analysis of cDNA for human renin precursor. *Proc Natl Acad Sci USA.* 1983;80:7405-7409.
17. Schweda F, Friis U, Wagner C, et al. Renin release. *Physiology (Bethesda).* 2007;22:310-319.
18. Sagnella GA. Why is plasma renin activity lower in populations of African origin? *J Hum Hypertens.* 2001;15:17-25.
19. Petersen TN, Brunak S, von Heijne G, Nielsen H. SignalP 4.0: discriminating signal peptides from transmembrane regions. *Nat Methods.* 2011;8:785-786.
20. Jagadeesh KA, Wenger AM, Berger MJ, et al. M-CAP eliminates a majority of variants of uncertain significance in clinical exomes at high sensitivity. *Nat Genet.* 2016;48:1581-1586.

21. Nagahama M, Nakayama K, Hori H, Murakami K. Expression of a deletion mutant of the prosegment of human prorenin in Chinese hamster ovary cells. *FEBS Lett.* 1989;259:202-204.
22. Nakayama K, Nagahama M, Kim WS, et al. Prorenin is sorted into the regulated secretory pathway independent of its processing to renin in mouse pituitary AtT-20 cells. *FEBS Lett.* 1989;257:89-92.
23. Mercure C, Thibault G, Lussier-Cacan S, et al. Molecular analysis of human prorenin prosegment variants in vitro and in vivo. *J Biol Chem.* 1995;270:16355-16359.
24. Guo H, Xiong Y, Witkowski P, et al. Inefficient translocation of preproinsulin contributes to pancreatic beta cell failure and late-onset diabetes. *J Biol Chem.* 2014;289:16290-16302.
25. Liu M, Lara-Lemus R, Shan SO, et al. Impaired cleavage of preproinsulin signal peptide linked to autosomal-dominant diabetes. *Diabetes.* 2012;61:828-837.
26. Arnold A, Horst SA, Gardella TJ, et al. Mutation of the signal peptide-encoding region of the preproparathyroid hormone gene in familial isolated hypoparathyroidism. *J Clin Invest.* 1990;86:1084-1087.
27. Hussain S, Mohd Ali J, Jalaludin MY, Harun F. Permanent neonatal diabetes due to a novel insulin signal peptide mutation. *Pediatr Diabetes.* 2013;14:299-303.
28. Demidyuk IV, Shubin AV, Gasanov EV, Kostrov SV. Propeptides as modulators of functional activity of proteases. *Biomol Concepts.* 2010;1:305-322.
29. Weiss MA. Diabetes mellitus due to the toxic misfolding of proinsulin variants. *FEBS Lett.* 2013;587:1942-1950.
30. Bentley AK, Rees DJ, Rizza C, Brownlee GG. Defective propeptide processing of blood clotting factor IX caused by mutation of arginine to glutamine at position -4. *Cell.* 1986;45:343-348.

31. Saraste J, Marie M. Intermediate compartment (IC): from pre-Golgi vacuoles to a semi-autonomous membrane system. *Histochem Cell Biol.* 2018;150:407-430.
32. Liu M, Sun J, Cui J, et al. INS-gene mutations: from genetics and beta cell biology to clinical disease. *Mol Aspects Med.* 2015;42:3-18.
33. Given BD, Mako ME, Tager HS, et al. Diabetes due to secretion of an abnormal insulin. *N Engl J Med.* 1980;302:129-135.
34. Sakura H, Iwamoto Y, Sakamoto Y, et al Structurally abnormal insulin in a diabetic patient. Characterization of the mutant insulin A3 (Val----Leu) isolated from the pancreas. *J Clin Invest.* 1986;78:1666-16672.
35. Shoelson S, Fickova M, Haneda M, et al. Identification of a mutant human insulin predicted to contain a serine-for-phenylalanine substitution. *Proc Natl Acad Sci US .* 1983;80:7390-7394.
36. Genome Aggregation Database [Available from:
https://gnomad.broadinstitute.org/gene/ENSG00000143839?dataset=gnomad_r3.
37. Pottel H, Hoste L, Dubourg L, et al. An estimated glomerular filtration rate equation for the full age spectrum. *Nephrol Dial Transplant.* 2016;31:798-806.

TABLES

Table 1. Distribution of heterozygous mutations causing ADTKD-REN mutations by mutation group and family.

| Mutation group | Mutation | Families (n) | Individuals (n) |
|------------------|----------|--------------|-----------------|
| Signal | p.W10R | 1 | 5 |
| | p.L12P | 1 | 1 |
| | p.L13Q | 1 | 1 |
| | p.delL16 | 6 | 28 |
| | p.L16P | 3 | 11 |
| | p.L16R | 2 | 9 |
| | p.W17R | 4 | 9 |
| | p.C20R | 3 | 5 |
| Signal total | | 21 | 69 |
| | | | |
| Prosegment | p.T26I | 2 | 19 |
| | p.M39K | 1 | 5 |
| | p.E48K | 1 | 3 |
| Prosegment total | | 4 | 27 |
| | | | |

| | | | |
|--------------|---------|----|-----|
| Mature | p.C325R | 1 | 3 |
| | p.I366N | 1 | 2 |
| | p.L381P | 1 | 5 |
| | p.T391R | 1 | 4 |
| | p.Q85H | 1 | 1 |
| Mature Total | | 5 | 15 |
| Total | | 30 | 111 |

Table 2. Characteristics according to mutation group.

| | Signal | Prosegment | Mature | P value |
|------------------------------------------------|------------|------------|------------------------|---------|
| Individuals | 69 (62%) | 27(24%) | 15(14%) | |
| Families | 21(70%) | 4(13%) | 5(17%) | |
| Age at presentation ¹ < 10 | 23(39%) | 11(61%) | 0 | 0.003 |
| Age at presentation ¹ 10 to < 20 | 19(32%) | 2(11%) | 0 | 0.02 |
| Age at presentation ¹ >20 | 17(29%) | 5(28%) | 12(100%) | <0.001 |
| Age at presentation (mean±s.d.) ^{1,2} | 19.7±15.7 | 22.4±20.2 | 37.0±12.4 ² | |
| Reason for presentation ^{1,2} | | | | 0.014 |
| Acute kidney injury | 5/55 (10%) | 0 | 0 | |
| Anemia, acidosis, kidney | 7/55(13%) | 0 | 0 | |

| | | | | |
|-------------------------------------------------|------------|------------|-----------------------|--------|
| failure | | | | |
| Anemia | 17/55(31%) | 7/14(50%) | 0 | |
| Chronic kidney disease | 12/55(22%) | 2/14(14%) | 3/12(25%) | |
| Gout | 14/55(25%) | 5/14(36%) | 9/12(75%) | |
| Total | 55 | 14 | 12 | |
| Anemia as child (%) | 39/43(91%) | 11/16(69%) | 0/7(0%) | <0.001 |
| Gout developed during the course of disease (%) | 31/55(56%) | 13/20(65%) | 9/14(64%) | 0.74 |
| Age at first gout attack (mean±s.d.) | 29.7±9.9 | 25.7±8.2 | 32.9±11.2 | 0.4 |
| Age at ESKD onset (mean±s.d.) | 53.1±10.6 | 50.8±17.6 | 63.6±7.6 ² | |

¹Excluding individuals who presented for asymptomatic genetic screening. Six of 61 (10%) in the signal group, 7/21 (33%) in the prosegment group, and 3/15 (20%) patients in the mature group were identified by asymptomatic genetic screening.

²p<0.001 when compared to the two other groups.

Table 3. Proportional hazards models including all individuals, with the event being age of end-stage kidney disease (ESKD). The univariate model showing anemia in childhood was also the best-fit multivariate model.

| Model | Risk | Reference | Hazard ratio | <i>P</i> value |
|------------|---------------------------------|---------------------------------------------------|--------------|----------------|
| Univariate | Mutation affecting mature renin | Mutations affecting signal peptide and prosegment | 0.367 | 0.023 |
| Univariate | Anemia in childhood | No anemia in childhood or unknown | 2.82 | 0.003 |
| Univariate | Male | Female | 0.92 | 0.80 |

Table 4. Characteristics of presentation according to gender for patients with signal peptide or prosegment mutations.

| | Female | Male | <i>P</i> value |
|---------------------------------------------|--------------|--------------|----------------|
| Individuals | 44 | 52 | 0.41 |
| Age at presentation ¹ < 10 | 18/35(48.6%) | 17/43(39.5) | 0.42 |
| Age at presentation ¹ 10 to < 20 | 9/35(25.7%) | 12/43(27.9%) | 0.85 |
| Age at presentation ¹ >20 | 9/35(25.7) | 13/43(30.2%) | 0.66 |
| Age at presentation (mean±s.d.) | 19.9±19.4 | 19.3±13.7 | 0.6 |
| Anemia as child (%) | 31/32(96.7%) | 19/27(45.8%) | 0.005 |
| Gout (%) | 15/38(39.5%) | 29/37(49.3%) | 0.0006 |
| Age at first gout attack (mean±s.d.) | 30.3±9.6 | 27.8±9.7 | 0.45 |
| Age at ESKD onset (mean±s.d.) | 50.1±11.4 | 55.8±10.5 | 0.25 |
| Serum potassium (mEq/L) (mean±s.d.) | 5.1±0.5 | 5.1±0.6 | 0.75 |
| Serum bicarbonate (mEq/L) (mean±s.d.) | 21.3±0.4 | 22.2±2.5 | 0.38 |

| | | | |
|----------------------------------------------------------------|---------|---------|------|
| Serum urate (mg/dL) without urate-lowering therapy (mean±s.d.) | 7.7±1.6 | 9.4±2.7 | 0.02 |
|----------------------------------------------------------------|---------|---------|------|

¹Excluding individuals who presented for asymptomatic genetic screening.

Table 5 REN mutations; a summary of *in vitro* characteristics

| Localization of the mutation | Cell lysate | | | | Culturing medium | | | | | | | | | Cellular localization |
|------------------------------|------------------|-----------------------------------------|---------------------------------|------------------------|------------------|------------|------------------------------------------|---------------------------------------|------------------------|----------------------------------------|-------------------------------------|------------------------|--------------------------------------------------------------------------------------------------------------|-----------------------|
| | Preprorenin (WB) | Prorenin (WB) IRMA % of wild type renin | Renin (WB) IRMA % of wild type) | Prorenin / Renin ratio | Prorenin (WB) | Renin (WB) | Prorenin IRMA assay % of wild type renin | Renin IRMA assay % of wild type renin | Prorenin / Renin ratio | Prorenin activity % of wild type renin | Renin activity % of wild type renin | Prorenin / Renin ratio | Immunofluorescence using anti-human preprorenin 288-317 antibody detecting preprorenin + prorenin + renin | |
| wild type protein | + | + 112±19 | + 100±13 | 1.1 | + | - | 705±71 | 100±4 | 7.5 | 100±6 | 100±4 | 1 | Coarsely granular structures in cytoplasm and lysosomes | |
| signal peptide del16L | + | + 4±3 | + 77±1 | 0.1 | + | - | 457±41 | 61±1 | 7.5 | 27±1 | 21±3 | 1.3 | Less distinct granular structures in cytoplasm and lysosomes | |
| signal peptide missense | + | - 2-3 | - 2-6 | 0 | - | - | 51-85 | 7-15 | 0 | 3-10 | 0-7 | 0 | Diffuse cytoplasmic staining | |
| prosegment T26I | + | + 72 | + 112 | 0.6 | + | - | 167±19 | 130±11 | 1.3 | 87 | 72 | 1.2 | Less distinct granular structures in cytoplasm and lysosomes with diffuse staining localized partly to ERGIC | |
| prosegment M39K | + | + 67 | + 81 | 0.8 | + | - | 7±33 | 238±24 | 0.03 | 64 | 255 | 0.25 | | |
| prosegment VUS_S45N | + | + 119±23 | + 64±16 | 1.9 | + | - | 768±170 | 66±12 | 11.6 | 97±4 | 88±5 | 1.1 | | |
| mature renin C325R | - | + 5 | + 7 | 0 | - | - | 0 | 0 | 0 | 0.1±0.1 | 0 | 0 | Intracellular clumps localized to ER | |
| AA variants | | | | | | | | | | | | | | |
| signal peptide P8A | + | + 132±26 | + 89±16 | 1.5 | + | - | 658±29 | 73±14 | 9 | 102±2 | 109±5 | 0.9 | Similar to wild type | |
| prosegment R33W | + | + 22±6 | + 30±3 | 0.7 | + | - | 67±7 | 74±22 | 0.9 | 37±1 | 103±5 | 0.4 | More diffuse pattern localized to ERGIC | |

Gray-shaded values are those significantly different from the wild type.

FIGURE LEGENDS

Figure 1. Age vs. estimated glomerular filtration rate (eGFR) in ADTKD-REN patients. A. All estimated glomerular filtration rate (eGFR) measurements for each group are included (signal group green, prosegment group red, mature group black). A best-fit line is included for each group. Patients in the mature group presented later in life and had normal kidney function at earliest measurement. Patients in the signal and prosegment group often presented early in life, and eGFR was significantly decreased from the time of first measurement in most patients. **B.** eGFR values in 13 children with longitudinal follow-up from the signal group. Each child is represented by a different color with a best-fit line, and the *REN* mutation is given in the legend. Despite having low eGFR values at earliest measurement, kidney function remained stable until age 20 in most patients.

Figure 2. End-stage kidney disease (ESKD) survival in ADTKD-REN individuals according to *REN* mutation group. This analysis included 111 individuals. An event was defined as starting dialysis or receiving a transplant. Censoring occurred if the individual had not reached ESKD by the end of the study period. Patients in the mature group had a later age of onset of ESKD compared to the signal and prosegment groups (hazards ratio = 0.237, $p=0.023$).

Figure 3. End-stage kidney disease (ESKD) survival according to presence of anemia in childhood. This analysis included 111 ADTKD-REN individuals. An event was defined as starting dialysis or receiving a transplant. Censoring occurred if the individual had not reached ESKD by the end of the study period. A diagnosis of anemia in childhood was associated with a worse prognosis (hazard ration 2.82, $p=0.03$).

Figure 4. Hemoglobin, hyperkalemia and acidemia in ADTKD-REN patients. White circles represent females and black circles represent males. **A.** Hemoglobin values according to age. For females, hemoglobin values were low throughout the period of measurement. For males, hemoglobin values began to rise at age 20. **B.** Serum potassium values according to age. Values remained consistent over time. **C.** Serum potassium according to estimated glomerular filtration rate (eGFR). **D.** Serum bicarbonate values according to age. There were many serum bicarbonate values <24 mEq/l.

Figure 5. ADTKD-REN treatment with fludrocortisone. This figure includes 13 young patients in signal (n=11) and prosegment groups (n=2), mutations are listed in the legend. The patient denoted with burgundy markers began fludrocortisone age 11, with an increase in eGFR that was sustained. The patient denoted with red markers started fludrocortisone at age 13.

Figure 6. *In silico* analysis of REN variants. (A) Preprorenin, a precursor of prorenin and renin, consists of : i) the signal peptide (SP) essential for targeting and insertion of the synthesized protein into the endoplasmic reticulum membrane, ii) the prosegment that determines the biosynthesis, cellular trafficking and enzymatic activity and iii) the mature enzymatically active renin that is formed upon the proteolytic cleavage of prorenin. Novel pathogenic mutations identified and characterized in this study are shown in red. Previously reported dominant mutations associated with ADTKD are shown in green. The p.S45N is considered nonpathogenic and is shown in blue. Variants of unknown significance identified in African-American variants are shown in yellow. Epitope 288-377 denotes the protein segment recognized by the anti-preprorenin antibody used in this study. The n, h and c regions respectively denote stretches of positively charged amino acids (n-region), hydrophobic amino acids (h-region) essential for targeting and insertion of the signal peptide into ER membrane, and polar amino

acids (c-region), forming a recognition site for the signal peptidase that releases translocated preproprotein from its ER membrane-anchored signal peptide. **(B)** Amino acids conservation across mutated segments of *REN* in higher mammals. Asterisks (*) indicate amino acid residues that are absolutely conserved, a colon (:) indicates residues with strong conservation and a dot (.) indicate residues with weak conservation between species. **(C)** Computational prediction by the SignalP 4.1 server of the impact of missense *REN* mutations located in the signal peptide on the conformation of the signal peptide cleavage site location (C-score) and on the sequence characteristics of the signal peptide (Y-score). SP denotes presence (YES/NO) of the signal peptidase cleavage site within the given sequence. The first 60 N-terminal amino acids of *REN* were used for this calculation. **(D)** Computational prediction by Mendelian Clinically Applicable Pathogenicity Score (M-CAP) of the pathogenicity of missense *REN* mutations located in the propeptide and mature renin.

Figure 7. Structural topology and impact of prosegment and renin mutations. The crystal structure of prorenin (PDB ID 3VCM) was used for modelling. The prorenin segment (amino acid residues 24-66) and the renin core (amino acid residues 67-406) are colored in magenta and green, respectively. The location of mutated residues is shown in the full structural model using red spheres. The effects of each mutation are illustrated in detail at individual images. Mutated residues and their interactions are highlighted as sticks and dashed lines. The mutation p.R33W loses polar contacts with Q241 and D248. Possible compensatory interactions between the proximal two beta-sheets are highlighted as three dashed lines. These changes decrease affinity between prorenin and renin. The mutation p.M39K causes steric clashes and charge repulsion with K100, resulting in decreased affinity between prorenin and renin. The nonpathogenic mutation p.S45N changes the interaction network, with S45 interacting with S41, while N45 interacts with L137 and D139. These changes increase affinity due to a changed interaction network. The mutation p.C325R disrupts a disulfide bridge (highlighted as sticks), and incorporation of

the arginine residue causes steric clashes (shown as red areas). The mutation p.I366N results in the loss of hydrophobic contacts (shown by red spheres) in the renin core.

Figure 8. Transient expression and functional characterization of REN variants in Human Embryonic Kidney 293 cells. The wild type renin (WT); signal peptide, prosegment and mature renin mutations; African-American (AA_REN) variants and empty vector were analyzed. **(A, B)** Western blot analysis of **(A)** cell lysates and **(B)** culture media. Molecular weights of immuno-reactive proteins present in the WT lysates correspond with expected molecular weights of prorenin (47 kDa), preprorenin (45 kDa) and renin (43 kDa). **(C, D)** Immunoradiometric assay (IRMA) of prorenin and renin amounts in **(C)** cell lysates and **(D)** culture media employing a radio-labeled antibody that specifically recognizes active site of renin. The concentration of prorenin was calculated as the difference between the renin concentration measured before and after trypsin treatment, which activates renin by proteolytic cleavage of the prosegment from prorenin. Amounts of mutated renin (grey bars) and prorenin (black bars) were normalized to the amount of wild type renin. The values represent means \pm SD. Measurements were performed in three independent clones for each of the constructs. The individual measurements were carried out in triplicate. The statistical significance of the differences between the WT and renin variants protein amounts was tested by t test. * $p < 0.05$; ** $p > 0.01$; *** $p > 0.001$; *n.d.* not done. **(E, F)** Enzymatic activity of **(E)** mature renin secreted into culture media and **(F)** prorenin secreted into culture media. The values were normalized to the WT (100%) and represent means \pm SD of relative fluorescent unit (RFU) generated by renin mediated cleavage of the 5-FAM and QXL520 conjugated renin substrate. Measurements were performed in three independent clones for each of the constructs. The individual measurements were carried out in triplicate. The statistical significance of the differences between activity of the wild type renin (WT) and renin variants was tested by t test. * $p < 0.05$; ** $p > 0.01$; *** $p > 0.001$; *n.d.* not done.

Figure 9. Transient expression and intracellular localization of transiently expressed mutated preprorenin, prorenin and renin in Human Embryonic Kidney 293 cells.

Preprorenin, prorenin and renin were detected using an antibody recognizing the epitope 288-317 of preprorenin and **(9A)** co-localized with a marker of endoplasmic reticulum intermediate compartment (ERGIC53); wild type protein was present in coarsely granular structures that were localized exclusively in the cytoplasm. Proteins with signal peptide mutations demonstrated either a very similar granular pattern (p.L16del) or intense diffuse cytoplasmic staining; (for detailed renin staining see Supplementary Figure S2). Proteins with prosegment mutations demonstrated a less distinct and more diffuse pattern that was localized mainly to ERGIC. The AA_*REN* variant p.P8A had similar staining pattern to the wild type. The AA_*REN* variant p.R33W demonstrated a less distinct and more diffuse pattern that was localized mainly to the ERGIC. Co-staining of renin with **(B)** protein disulphide isomerase (PDI), a marker of endoplasmic reticulum (ER) demonstrating localization of mature renin mutations in the ER. The degree of renin colocalization with selected markers is demonstrated by the fluorescent signal overlap coefficient values that ranging from 0-1. The resulting overlap coefficient values are presented as the pseudo color which scale is shown in corresponding lookup table.

Figure 10. Pathophysiology of *ADTKD-REN*. **(A)** Wild type preprorenin is cotranslationally translocated into the ER. The signal sequence is cleaved during translocation, and nascent prorenin is glycosylated. Prorenin then transits through the ER-Golgi Intermediate Compartment (ERGIC), which monitors proper protein folding and detects aberrant protein forms. In the Golgi apparatus prorenin is both sorted to clear vesicles and constitutively secreted to proto-granules, where it is proteolytically processed to renin, which is later subjected to regulated secretion. **(B)** Mutations in the signal peptide prevent translocation across the ER membrane, and the preprorenin is aberrantly located in the cytoplasm. This

results in clinical renin deficiency and ER stress in renin producing cells. Mutations in the mature renin lead to retention of mutated protein in ER. This initiates ER stress similar to that seen in *UMOD* mutations and uromodulin retention in *ADTKD-UMOD*. Mutations in the prosegment introduce structural changes affecting protein biosynthesis, folding and travel along the secretory pathway causing clinical renin deficiency and potentially also cellular toxicity leading to chronic kidney disease.

SUPPLEMENTARY MATERIALS

Supplementary Figures

Figure S1. Flow diagram of the ADTKD-*REN* International Cohort

Figure S2. Representative family trees from 3 families with dominant *REN* mutations

Figure S3. Intracellular localization of transiently expressed mutated preprorenin, prorenin and renin in Human Embryonic Kidney 293 cells

Figure S4. Localization of transiently expressed mutated preprorenin, prorenin and renin in Golgi apparatus of Human Embryonic Kidney 293 cells

Figure S5. Localization of transiently expressed mutated preprorenin, prorenin and renin in lysosomes of Human Embryonic Kidney 293 cells

Figure S6. Colocalization of transiently expressed mutated preprorenin, prorenin and renin in ERGIC of Human Embryonic Kidney 293 cells

Supplementary Methods

Transient expression of preprorenin in HEK293 cells

Western blot analysis

Quantitative analysis of renin and prorenin by immunoradiometric assay (IRMA)

Measurement of the enzymatic activity of renin secreted into the culture media

Confocal microscopy

Image acquisition and analysis

Supplementary References

Figure 1




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6




Figure 7




Figure 8





Figure 9A



SUPPLEMENTARY MATERIAL: Distinct subtypes of ADTKD-REN in an international cohort study

Figure 9B





Figure 10



SUPPLEMENTARY MATERIAL

This material provides additional information for the article:

An International Cohort Study of Autosomal Dominant Kidney Disease due to *REN* Mutations

Identifies Distinct Subtypes

Authors:

Martina Živná, PhD¹, Kendrah Kidd, MS^{1,2}, Mohamad Zaidan, MD, PhD³, Petr Vyleťal, PhD¹, Veronika Barešová, PhD¹, Kateřina Hodaňová, PhD¹, Jana Sovová¹, Hana Hartmannová, PhD¹, Miroslav Votruba¹, Helena Trešlová¹, Ivana Jedličková¹, Jakub Sikora¹, Helena Hůlková¹, Victoria Robins², Aleš Hnízda⁴, Jan Živný, PhD⁵, Gregory Papagregoriou, PhD⁶, Laurent Mesnard, MD⁸, Bodo B. Beck^{8,9}, Andrea Wenzel, PhD^{8,9}, Kálmán Tory, MD, PhD^{10,11}, Karsten Häeffner, MD¹², Matthias T.F. Wolf, MD¹³, Michael E. Bleyer, BS², John A. Sayer, MD PhD¹⁴⁻¹⁶, Albert C. M. Ong, DM¹⁷, Lídia Balogh, MD, PhD¹¹, Anna Jakubowska, MD¹⁸, Agnieszka Łaszkiwicz, PhD¹⁹, Rhian Clissold, MB ChB, MD²⁰, Charles Shaw-Smith, MD²⁰, Raj Munshi, MD^{21,22}, Robert M. Haws, MD²³, Claudia Izzi, MD²⁴, Irene Capelli, MD²⁵, Marisa Santostefano, MD²⁶, Claudio Graziano, MD²⁷, Francesco Scolari, MD, PhD²⁴, Amy Sussman, MD²⁸, Howard Trachtman, MD²⁹, Stephane Decramer, MD, PhD^{30,31}, Marie Matignon, MD^{32,33}, Philippe Grimbert, MD³²⁻³⁴, Lawrence R. Shoemaker, MD³⁵, , Christoforos Stavrou, MD³⁶, Mayssa Abdelwahed, PhD³⁷, Neila Belghith, MD^{37,38}, Matthew Sinclair, MD^{39,40}, Kathleen Claes, MD, PhD^{41,42}, Tal Kopel, MD⁴³, Sharon Moe, MD⁴⁴, Constantinos Deltas, PharmR, PhD⁶, Bertrand Knebelmann, MD, PhD⁴⁵⁻⁴⁷, Luca Rampoldi, PhD⁴⁸, Stanislav Kmoch, PhD^{1,2}, Anthony J. Bleyer, MD, MS^{1,2}

Corresponding Author

Anthony J. Bleyer, MD, MS; Wake Forest School of Medicine; Section on Nephrology; Winston-Salem, NC, USA 27157; Fax: 336-716-4318; Phone: 336-716-4650; e-mail: ableyer@wakehealth.edu

SUPPLEMENTARY MATERIAL: Distinct subtypes of ADTKD-REN in an international cohort study

Table of Contents

Supplementary Figures

| | |
|-------------------------------------------------------------------------------------------------------------------------------------------------------|----|
| Figure S1. Flow diagram of the ADTKD-REN International Cohort..... | 3 |
| Figure S2. Representative family trees from 3 families with dominant <i>REN</i> mutations..... | 4 |
| Figure S3. Intracellular localization of transiently expressed mutated preprorenin, prorenin and renin in Human Embryonic Kidney 293 cells..... | 5 |
| Figure S4. Localization of transiently expressed mutated preprorenin, prorenin and renin in Golgi apparatus of Human Embryonic Kidney 293 cells | 6 |
| Figure S5. Localization of transiently expressed mutated preprorenin, prorenin and renin in lysosomes of Human Embryonic Kidney 293 cells..... | 8 |
| Figure S6. Colocalization of transiently expressed mutated preprorenin, prorenin and renin in ERGIC of Human Embryonic Kidney 293 cells..... | 10 |

Supplementary Methods

| | |
|-------------------------------------------------------------------------------------|-----------|
| Transient expression of preprorenin in HEK293 cells | 11 |
| Western blot analysis..... | 11 |
| Quantitative analysis of renin and prorenin by immunoradiometric assay (IRMA)..... | 13 |
| Measurement of the enzymatic activity of renin secreted into the culture media..... | 13 |
| Confocal microscopy..... | 14 |
| Image acquisition and analysis | 14 |
| Supplementary References | 15 |

SUPPLEMENTARY MATERIAL: Distinct subtypes of ADTKD-REN in an international cohort study




Figure S1. Flow diagram of the ADTKD-REN International Cohort. Twelve academic centers with an interest in ADTKD contributed 68 patients from 14 families previously not reported. Wake Forest School of Medicine-Charles University contributed six patients from four families previously not reported and 18 patients from four families published (S1-S2). Literature review yielded five papers describing 19 patients from five families (S3-S7).

SUPPLEMENTARY MATERIAL: Distinct subtypes of ADTKD-REN in an international cohort study




Figure S2. Representative family trees from three families with dominant *REN* mutations. Clear symbols represent clinically unaffected and filled symbols represent clinically affected. Individuals with 1 asterisk (*) underwent genetic testing and were negative. Individuals with 2 asterisks (**) underwent genetic testing and were positive for a pathogenic *REN* mutation, mutation is given below the family tree. Family trees are also found in references S1-S7.

SUPPLEMENTARY MATERIAL: Distinct subtypes of ADTKD-REN in an international cohort study




Figure S3. Intracellular localization of transiently expressed mutated preprorenin, prorenin and renin in Human Embryonic Kidney 293 cells. Immunofluorescence detection with an antibody recognizing the epitope 288-317 of preprorenin demonstrates that the wild type protein is present in coarsely granular structures that are localized exclusively in the cytoplasm. Proteins with the mutations in the signal peptide demonstrate either a very similar granular pattern (pL16del) or intense diffuse cytoplasmic staining. Proteins with mutations in the prosegment and renin demonstrate a less distinct and more diffuse pattern.

SUPPLEMENTARY MATERIAL: Distinct subtypes of ADTKD-REN in an international cohort study




Figure S4.

Figure S4. Localization of transiently expressed mutated preprorenin, prorenin and renin in Golgi apparatus of Human Embryonic Kidney 293 cells. Immunofluorescent costaining of renin (REN) with an antibody recognizing the epitope 288-317 of preprorenin and Golgi apparatus with mouse anti-GM130 (GM130) showing limited localization of wild type and mutant proteins in Golgi. The degree of renin colocalization with selected marker is demonstrated by the fluorescent signal overlap coefficient values that ranging from 0-1. The resulting overlap coefficient values are presented as the pseudo color which scale is shown in corresponding lookup table.

SUPPLEMENTARY MATERIAL: Distinct subtypes of ADTKD-REN in an international cohort study




Figure S5.

Figure S5. Localization of transiently expressed mutated preprorenin, prorenin and renin in lysosomes of Human Embryonic Kidney 293 cells. Immunofluorescent costaining of renin (REN) with an antibody recognizing the epitope 288-317 of preprorenin and lysosome with Mouse anti-LAMP2 showing localization of the wild type protein, the protein with signal peptide mutation L16del and proteins with prosegment mutations (T26I, M39K and S45N) in lysosomes. Proteins with other signal peptide mutations (L13Q and L16P) and protein with mutations in the mature renin (C325R) did not localize to lysosomes. The degree of renin colocalization with selected marker is demonstrated by the fluorescent signal overlap coefficient values that ranging from 0-1. The resulting overlap coefficient values are presented as the pseudo color which scale is shown in corresponding lookup table.

SUPPLEMENTARY MATERIAL: Distinct subtypes of ADTKD-REN in an international cohort study

| Variant | Location | Pearson's coefficient | Avg | SmOdch |
|---------|---------------|-----------------------|-------|--------|
| WT | | 0,18 - 0,22 | 0.2 | 0.02 |
| L16del | SP | 0,18 - 0,29 | 0.235 | 0.055 |
| C20R | SP | 0,24 - 0,37 | 0.305 | 0.065 |
| L13Q | SP | 0,27 - 0,36 | 0.29 | 0.02 |
| L16P | SR | 0,52 - 0,55 | 0.535 | 0.015 |
| W17R | SP | 0,25 - 0,31 | 0.28 | 0.03 |
| T26I | Prosegment | 0,59 - 0,72 | 0.675 | 0.085 |
| M39K | Prosegment | 0,68 - 0,76 | 0.72 | 0.04 |
| S45N | Prosegment | 0,69 - 0,84 | 0.765 | 0.075 |
| C325R | Mature REN | 0,29 - 0,36 | 0.325 | 0.035 |
| P8A | AA_REN (SP) | 0,12 - 0,32 | 0.22 | 0.1 |
| R33W | AA_REN (Pros) | 0,59 - 0,66 | 0.625 | 0.035 |




Figure S6. Colocalization of transiently expressed mutated preprorenin, prorenin and renin in ERGIC of Human Embryonic Kidney 293 cells. The Pearson's correlation coefficients of the degree of colocalization of wild type and mutated renin and ERGIC were calculated for 10 transfected cells in the Huygens Professional Software; (y-axis). +1 represents perfect correlation, 0.5 random colocalization and 0 no correlation. Representative immunofluorescence staining is shown in Figure 9.

SUPPLEMENTARY MATERIAL: Distinct subtypes of ADTKD-REN in an international cohort study

Supplementary Methods

Transient expression of preprorenin in HEK293 cells

8 x 10⁵ HEK 293 cells were seeded on a 6-well plate and grown for 24 hours in DMEM with 10% FCS and 1 mM HEPES (pH 7.31) containing DMEM/F12 media (Gibco) supplemented with 10% fetal calf serum (Gibco) and penicillin / streptomycin at 100 U/ml and 100 µg/ml, respectively, at 37 °C in a 5% CO₂ atmosphere (Sigma). After 24 hours, cells were transfected with Lipofectamine TM2000 with 4µg of appropriate cDNA constructs and grown either in serum-free medium without phenol red (for western blot and enzymatic activity analysis) or fully supplemented medium with phenol red (for IRMA analysis). At 24 hours after transfection, 1 mL media from each type was collected. Cells were mechanically harvested either by PBS1x for quantitative analysis of synthesized renin and prorenin (IRMA method) or lysed by lysis buffer with Protease Inhibitor Cocktail followed by qualitative study (western blot). For IRMA analysis, the amount of renin and prorenin were normalized to total protein concentration in lysates. Total protein concentration was determined using Bradford solution according to the manufacturer protocol (BioRad). Absorbance was measured by the Infinite 200 Pro reader (Tecan, Austria, GmbH) at 595 nm.

Western blot analysis

Cells cultured in FBS and phenol red-free medium were harvested to PBS and pelleted at 800g/7 min/RT. Pellets were resuspended in SDS-PAGE sample buffer (50 mM Tris HCl, 50 mM DTT, 2% SDS, pH 6,8) with Protease Inhibitor Cocktail (Sigma, Prague, Czech Republic) added in a 100:1 ratio and incubated on ice for 3 hours. Lysates were sonicated 3 times for 10 sec with an Ultrasonic Homogenizer 4710 (Cole-Palmer Instruments, Vernon Hills, IL, USA) equipped with cup horn filled with ice cold water, denatured at 100°C/5 min, cooled on ice and stored at -20°C. The protein concentration in lysates was measured by

SUPPLEMENTARY MATERIAL: Distinct subtypes of ADTKD-REN in an international cohort study

Direct Detect[®] Infrared Spectrometer (Merck Millipore, Billarica, MA, USA), according to manufacturer's instructions.

For the secreted renin analysis, FBS and phenol red-free cell culture media were aspirated, mixed with a Protease inhibitor cocktail in 100:1 ratio and successively cleared at 800g/7 min and 15000g/5 min at RT. Supernatants were concentrated on Amicon[®] Ultra – 0.5mL Centrifugal Filters 10K (Merck Millipore, Tullagreen, Ireland) to minimal volume (about 20 µl) according to manufacturer's instructions.

Concentrated media were stored at -20°C.

Volumes of lysates and media equivalent to 15 µg of proteins and 250000 cells, respectively, were mixed with 6X SDS-PAGE sample buffer (350 mM Tris Base, 10% SDS, 6% BME, 30% glycerol, 0,012% BPB, pH 6,8) in 0,2 mL tubes, denatured at 100°C/5 minutes and resolved on 4% stacking and 10% separating gel at 75 V and 150 V, respectively, in MightySmall II SE260 or SE640 apparatus (Hoefer, San Francisco, CA, USA). Proteins were then transferred to methanol-activated PVDF membrane in semi-dry blotting apparatus PHERO-Multiblot (Biotec-Ficher, Reiskirchen, Germany) at 0.6 mA/cm² for 60 minutes. Membrane was blocked in phosphate-buffered saline with 0.1% Tween 20 (PBST) and 5% BSA and probed with rabbit preprorenin (288-317) diluted 1:3000 in PBST with 0.1% BSA followed by HRP-conjugated Goat anti-Rabbit IgG (H+L) secondary antibody (Thermo Fisher Scientific, Prague, Czech Republic) at 1:10,000 dilution.

Membranes were incubated with Clarity[™] Western ECL Substrate (Bio-Rad, Prague, Czech Republic) according to manufacturer's instructions. Signal was captured on CP-BU Medical X-ray blue film (Agfa) developed by Fomadent solution set (Foma Bohemia, Tisice-Chrast, Czech Republic). The tubulin protein was visualized by incubation with Mouse anti-Acetylated tubulin (T6793, Sigma Aldrich) at dilution

SUPPLEMENTARY MATERIAL: Distinct subtypes of ADTKD-REN in an international cohort study

1:3000 in 0.1% BSA and 0.1% Tween 20 in PBS for 1 hour at RT, followed by incubation with Goat anti-Mouse HRP (Pierce) under conditions and using detection as described above.

Quantitative analysis of renin and prorenin by immunoradiometric assay (IRMA)

Cell lysate was prepared as described above. The medium was centrifuged at 15,000 x g for 10 min, and the resulting supernatant was mixed with protease inhibitor cocktail in ratio 100:1 (vol/vol).

For renin determination, 50 µl of the medium and 5 µl of the lysate were diluted to a final volume of 200µl with PBS. For trypsin-activated total renin and prorenin amount, 5µl of medium and 2.5µl of lysate were incubated at 37°C for 30 min in a 50µl PBS reaction containing 100 µg and 400 µg of trypsin, respectively. The reactions were stopped by 1µl of 10 mg/mL trypsin inhibitor (PMSF, Roche, Prague, Czech Republic) and diluted to a final volume of 200 µl with PBS.

Ten µl of the resulting mixtures was mixed with 290 µl of PBS and 100 µl of the anti-hRenin (I-125) reagent (Renin III Generation Kit, CISBIO Bioassays, France), and the renin amount was measured according to manufacturer's instructions.

Measurement of the enzymatic activity of renin secreted into the culture media

We measured the enzymatic activity of renin before and after cleavage of the propeptide region and of prorenin secreted into culture media after transient expression of renin variants and wild type renin.

Seeding, maintaining and transfection were performed as described above. Twenty four hours after lipofection, the medium was collected and divided into 2 tubes. Trypsin / EDTA 1x (volume ratio medium : T/E = 1: 3) was added to one tube and incubated 30 min at 37°C for cleavage of prosegment from prorenin. The trypsin reaction was stopped by adding of 2,6 µL of 50mM PMSF (Roche) and incubated for 15 min at room temperature. 100µL media before and after trypsin incubation were placed into a

SUPPLEMENTARY MATERIAL: Distinct subtypes of ADTKD-REN in an international cohort study

96-well plate and 50 μ L of 100x diluted renin substrate conjugated with 5-FAM and QXL520 was added (part of Sensolyte 520 Renin Assay Kit, AnaSpec, San Jose, CA). The fluorescent signal was monitored at 528 nm every 15 min for 3 hr at 37°C on an Infinite 2000Pro microplate reader (Tecan, Austria). Each sample either before or after trypsin activation was measured in triplicate. For graph construction, we used values after 75 minutes from the start of measurement, which was the time of maximum signal in linear part of enzymatic curves.

Confocal microscopy

1,5 x 10⁵ HEK293 cells were plated on polysinated glass coverslips for 24 hours and transiently transfected by LipofectamineTM3000 with 1 μ g plasmid DNA of wt renin, L16del, C20R, L13Q, L16P, W17R, T26I, M39K, C325R, I366N, P8A, R33W, respectively according to the manufacturer's protocol. 24 hours after lipofection, cells were quickly washed with PBS1x and fixed with cold 100% methanol. After fixing, cells were washed three times in PBS 1x and proteins were blocked for 30 min at room temperature in PBS with 5% FCS. Cells were incubated over night at 4°C with rabbit primary antibody anti-human preprorenin 288-317 (Yanaihara) at a dilution of 1:50 or mouse anti-PDI (Enzo) at a dilution 1:200 or mouse anti-ERGIC (Acris) at a dilution 1:200. For colocalization with Golgi Apparatus we used mouse anti-GM130 (ab 169276, Abcam) at a dilution of 1:300. For colocalization with lysosomes we used mouse anti-LAMP2 (H4B4) (ab 25631, Abcam) at a dilution of 1:500. Cells were washed five times in PBS 1x and incubated with donkey anti-rabbit Alexa Fluor 555 and goat anti-mouse Alexa Fluor 488 (Invitrogen) at dilution 1:1000. All antibodies were diluted in PBS 1x with 5% FCS and 0.05% Tween 20. Cells were washed four times and mounted into Antifade with DAPI (Invitrogen) for confocal imaging.

Image acquisition and analysis

Prepared slides were analyzed by confocal microscopy. XYZ images were sampled according to Nyquist criterion using a LeicaSP8X laser scanning confocal microscope, HC PL APO objective (63x, N.A. 1.40),

SUPPLEMENTARY MATERIAL: Distinct subtypes of ADTKD-REN in an international cohort study

405, 488 and 543 laser lines. Images were restored using a classic maximum likelihood restoration algorithm in the Huygens Professional Software (SVI, Hilversum, The Netherlands). The colocalization maps employing single pixel overlap coefficient values ranging from 0-1, were created and the colocalization coefficients were calculated in the Huygens Professional Software. The resulting overlap coefficient values are presented as the pseudo color which scale is shown in corresponding lookup tables (LUT). Approximately ten cells per variant were analyzed.

Supplementary References

S1. Zivna M, Hulkova H, Marignon M, et al. Dominant renin gene mutations associated with early-onset hyperuricemia, anemia, and CKD. *Am J Human Genet.* 2009;85:204-213

S2. Bleyer AJ, Zivna M, Hulkova H, et al. Clinical and molecular characterization of a family with a dominant renin gene mutation and response to treatment with fludrocortisone. *Clin Nephrol.* 2010;74:411-422

S3. Beck BB, Trachtman H, Gitman M, et al. Autosomal dominant mutation in the signal peptide of renin in a kindred with anemia, hyperuricemia, and CKD. *Am J Kidney Dis.* 2011;58:821-825.

S4. Clissold RL, Clarke HC, Spasic-Boskovic O, et al. Discovery of a novel dominant mutation in the REN gene after forty years of renal disease: a case report. *BMC Nephrol.* 2017;18:23

S5. Petrijan T, Menih M. Discovery of a Novel Mutation in the REN Gene in Patient With Chronic Progressive Kidney Disease of Unknown Etiology Presenting With Acute Spontaneous Carotid Artery Dissection. *J Stroke Cerebrovasc Dis.* 2019;28:104302.

S6. Abdelwahed M, Chaabouni Y, Michel-Calemard L, et al. A novel disease-causing mutation in the Renin gene in a Tunisian family with autosomal dominant tubulointerstitial kidney disease. *Int J Biochem Cell Biol.* 2019;117:105625.

SUPPLEMENTARY MATERIAL: Distinct subtypes of ADTKD-REN in an international cohort study

S7. Schaeffer C, Izzi C, Vettori A, et al. Autosomal Dominant Tubulointerstitial Kidney Disease with Adult Onset due to a Novel Renin Mutation Mapping in the Mature Protein. *Sci Rep.* 2019;9:11601.